|Articles|January 1, 2002

TNF blockers control psoriatic arthritis

San Francisco - Both tumor necrosis factor (TNF) blockers etanercept and infliximab continue to play an emerging role in the treatment of psoriatic arthritis (PsA), according to two new studies presented at the American College of Rheumatology annual meeting here.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME